All In Biotech

Drug Trial Radar · NCT06167486

SG2918 For Advanced Malignant Tumors

A Phase I Clinical Study to Evaluate the Safety Tolerability and Preliminary Efficacy of SG2918 in Subjects With Advanced Malignant Tumors

Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

17

Actual

Start

Dec 26, 2023

Primary completion

Nov 11, 2025

Study completion Nov 11, 2025

Sponsor

Sponsor type
Industry
First posted
Dec 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I, open-label, dose escalation and dose expansion study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SG2918 in subjects with Advanced Malignant Tumors who are refractory or resistant to standard therapy, or without available standard or curative therapy.

Conditions

  • Advanced Malignant Tumors

Interventions

  • SG2918Drug

    The SG2918 will be administrated by intravenous infusion every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse EventsTime frame: From the time of first dose until 30 days after last dose of SG2918
  2. Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)Time frame: Cycle 1 (up to 21 days)

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Shanghai first maternity and infant hospital

    Shanghai, Shanghai Municipality, China

  • Shanxi Provincial Cancer Hospital

    Taiyuan, Shanxi, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.